FDA Clears Spiriva HandiHaler Of Increased Cardiovascular Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Two years after an Early Communication about potential risk and two years months after an advisory gave it the thumbs ups, Boehringer Ingleheim's COPD therapy gets an official FDA announcement that it does not appear to be linked to increased CV events.